Cargando…

Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design

Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciccone, Lidia, Tonali, Nicoló, Nencetti, Susanna, Orlandini, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301710/
https://www.ncbi.nlm.nih.gov/pubmed/32419519
http://dx.doi.org/10.1080/14756366.2020.1760262
_version_ 1783547741832478720
author Ciccone, Lidia
Tonali, Nicoló
Nencetti, Susanna
Orlandini, Elisabetta
author_facet Ciccone, Lidia
Tonali, Nicoló
Nencetti, Susanna
Orlandini, Elisabetta
author_sort Ciccone, Lidia
collection PubMed
description Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological condition carries thyroxine (T(4)) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer’s disease (AD). However, TTR also is an amyloidogenic protein responsible for familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The TTR amyloidogenic potential is speeded up by several point mutations. One therapeutic strategy against TTR amyloidosis is the stabilisation of the native tetramer by natural compounds and small molecules. In this review, we examine the natural products that, starting from 2012 to present, have been studied as a stabiliser of TTR tetramer. In particular, we discussed the chemical and structural features which will be helpful for future drug design of new TTR stabilisers.
format Online
Article
Text
id pubmed-7301710
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-73017102020-06-25 Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design Ciccone, Lidia Tonali, Nicoló Nencetti, Susanna Orlandini, Elisabetta J Enzyme Inhib Med Chem Review Article Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological condition carries thyroxine (T(4)) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer’s disease (AD). However, TTR also is an amyloidogenic protein responsible for familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The TTR amyloidogenic potential is speeded up by several point mutations. One therapeutic strategy against TTR amyloidosis is the stabilisation of the native tetramer by natural compounds and small molecules. In this review, we examine the natural products that, starting from 2012 to present, have been studied as a stabiliser of TTR tetramer. In particular, we discussed the chemical and structural features which will be helpful for future drug design of new TTR stabilisers. Taylor & Francis 2020-05-18 /pmc/articles/PMC7301710/ /pubmed/32419519 http://dx.doi.org/10.1080/14756366.2020.1760262 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ciccone, Lidia
Tonali, Nicoló
Nencetti, Susanna
Orlandini, Elisabetta
Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title_full Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title_fullStr Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title_full_unstemmed Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title_short Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
title_sort natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301710/
https://www.ncbi.nlm.nih.gov/pubmed/32419519
http://dx.doi.org/10.1080/14756366.2020.1760262
work_keys_str_mv AT cicconelidia naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign
AT tonalinicolo naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign
AT nencettisusanna naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign
AT orlandinielisabetta naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign